Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 887 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR New ESMO President 2029-2030 Elected June 3, 2026 Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies... November 20, 2021 10 Things Diet Soda Does to Your Body If You Drink... July 29, 2021 Self Destruction September 8, 2022 Load more HOT NEWS Study Estimates That 22% Of Breast Cancers Are Overdiagnosed And Won’t... Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... FDA Approves Durvalumab for Muscle Invasive Bladder Cancer FDA Approves Belzutifan for Advanced Renal Cell Carcinoma
